GlassScriptPhysician profile
Julia Vega
NPI 1992180517
$6,055.87
in general payments reported to CMS, 2019-2025
45 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $451 · 2022: $700 · 2023: $1,459 · 2024: $2,062 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,481 · Education: $424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,480.97 |
| Education | $424.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $769.17 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $757.93 | 2021-2025 | |
| Seagen INC. | $654.97 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Celgene Corporation | $402.01 | 2023-2025 | Reblozyl |
| Genzyme Corporation | $315.89 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $282.03 | 2021-2025 | Enhertu, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $217.32 | 2021-2025 | |
| Genentech USA, INC. | $175.26 | 2022-2025 | Polivy, Phesgo, Rozlytrek |
| Abbvie INC. | $171.37 | 2022-2025 | |
| Glaxosmithkline, LLC. | $169.53 | 2021-2024 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $146.77 | 2023-2025 | Ninlaro, Iclusig, Fruzaqla |
| Astellas Pharma US INC | $139.66 | 2024-2025 | Padcev |
| Ipsen Biopharmaceuticals, INC | $136.27 | 2021-2024 | Onivyde |
| Beigene USA, INC. | $132.48 | 2021-2024 | Brukinsa |
| Eisai INC. | $130.19 | 2023-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $121.99 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $108.40 | 2021-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $104.77 | 2021-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $101.60 | 2022-2023 | Keytruda, Lynparza |
| Axonics, INC. | $92.56 | 2023 | Bulkamid |
| Sanofi-Aventis U.S. LLC | $83.00 | 2024 | |
| Puma Biotechnology, INC. | $82.50 | 2022-2024 | |
| Exelixis INC. | $70.96 | 2024-2025 | Cabometyx |
| Lilly USA, LLC | $65.01 | 2023-2025 | Verzenio, Jaypirca |
| Mirati Therapeutics, INC. | $63.60 | 2023-2024 | Krazati |
| Sobi, INC | $60.77 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $56.19 | 2022-2025 | |
| Array Biopharma INC | $53.47 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Alexion Pharmaceuticals, INC. | $38.12 | 2023-2024 | Ultomiris |
| Caris Mpi, INC. | $37.50 | 2025 | Mi Cancer Seek |
| Janssen Pharmaceuticals, INC | $35.98 | 2022-2023 | Xarelto |
| Taiho Oncology, INC. | $32.95 | 2024 | |
| Foundation Medicine, INC. | $27.26 | 2023 | Foundationone Liquid Cdx |
| Stemline Therapeutics INC. | $26.59 | 2023 | Orserdu |
| Incyte Corporation | $22.50 | 2024 | Jakafi |
| G1 Therapeutics, INC. | $21.27 | 2023 | Cosela |
| Eusa Pharma (US) LLC | $19.30 | 2021 | |
| Exact Sciences Corporation | $18.55 | 2025 | Cologuard Collection Kit |
| Emd Serono, INC. | $18.21 | 2024 | |
| Acrotech Biopharma INC. | $17.54 | 2024 | Beleodaq |
| Global Blood Therapeutics, INC. | $16.50 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.11 | 2023 | Libtayo |
| Karyopharm Therapeutics INC. | $14.80 | 2023 | Xpovio |
| Myriad Genetic Laboratories, INC. | $14.35 | 2025 | Myrisk |
| Deciphera Pharmaceuticals INC. | $13.67 | 2025 | Qinlock, Tgct |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Vega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.